A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept
With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2016/4095852 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563808194789376 |
|---|---|
| author | Sophie Seguin-Greenstein Sue Lightman Oren Tomkins-Netzer |
| author_facet | Sophie Seguin-Greenstein Sue Lightman Oren Tomkins-Netzer |
| author_sort | Sophie Seguin-Greenstein |
| collection | DOAJ |
| description | With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) were included. Weighted mean difference (WMD) and 95% CI were estimated using the standardized mean change method. The overall results of the meta-analysis showed a small but statistically significant improvement in BCVA six months following treatment switch to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; p=0.04), and the effect was more significant in data gathered from prospective studies (WMD 0.407, 95% CI 0.023 to 0.791, p=0.038). There was a significant improvement in CRT following treatment switch to aflibercept (WMD −0.36, 95% CI −0.485 to −0.235; p<0.0001). Our meta-analysis indicates that following treatment switch to aflibercept patients may have a significant improvement in CRT with stabilization or even some improvement in their visual acuity. |
| format | Article |
| id | doaj-art-dea894a2e3924a16a8feecee25bea52f |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-dea894a2e3924a16a8feecee25bea52f2025-02-03T01:12:29ZengWileyJournal of Ophthalmology2090-004X2090-00582016-01-01201610.1155/2016/40958524095852A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with AfliberceptSophie Seguin-Greenstein0Sue Lightman1Oren Tomkins-Netzer2Moorfields Eye Hospital, 162 City Road, London EC1V 2PD, UKMoorfields Eye Hospital, 162 City Road, London EC1V 2PD, UKMoorfields Eye Hospital, 162 City Road, London EC1V 2PD, UKWith the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central retinal thickness (CRT) were included. Weighted mean difference (WMD) and 95% CI were estimated using the standardized mean change method. The overall results of the meta-analysis showed a small but statistically significant improvement in BCVA six months following treatment switch to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; p=0.04), and the effect was more significant in data gathered from prospective studies (WMD 0.407, 95% CI 0.023 to 0.791, p=0.038). There was a significant improvement in CRT following treatment switch to aflibercept (WMD −0.36, 95% CI −0.485 to −0.235; p<0.0001). Our meta-analysis indicates that following treatment switch to aflibercept patients may have a significant improvement in CRT with stabilization or even some improvement in their visual acuity.http://dx.doi.org/10.1155/2016/4095852 |
| spellingShingle | Sophie Seguin-Greenstein Sue Lightman Oren Tomkins-Netzer A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept Journal of Ophthalmology |
| title | A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept |
| title_full | A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept |
| title_fullStr | A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept |
| title_full_unstemmed | A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept |
| title_short | A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with Aflibercept |
| title_sort | meta analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age related macular degeneration following switching to treatment with aflibercept |
| url | http://dx.doi.org/10.1155/2016/4095852 |
| work_keys_str_mv | AT sophieseguingreenstein ametaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept AT suelightman ametaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept AT orentomkinsnetzer ametaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept AT sophieseguingreenstein metaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept AT suelightman metaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept AT orentomkinsnetzer metaanalysisofstudiesevaluatingvisualandanatomicaloutcomesinpatientswithtreatmentresistantneovascularagerelatedmaculardegenerationfollowingswitchingtotreatmentwithaflibercept |